For example, targeting SERPING1 to modulate complement activation could be beneficial in treating autoimmune conditions, while IGFBP3 could be explored as a therapeutic agent in cancer and metabolic disorders due to its regulatory influence on cell growth and survival.31 Here, SERPING1 is linked to metabolic disease.